Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business funding round

Basecamp Research $140M Series C for AI Therapeutics

Analysis based on 7 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026

Sentiment
15
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The round signals continued strong venture appetite for AI-driven drug discovery, supporting valuations across the AI-biotech intersection and reinforcing Nvidia's and Anthropic's strategic positioning in life sciences. It is a modest positive for the broader biotech funding environment but unlikely to move large-cap indices materially.

biotechnology artificial intelligence pharmaceuticals

Basecamp Research, a London-based frontier AI company developing AI-designed medicines, announced an oversubscribed $140M Series C financing on September 23, 2026. The round was led by S32, with participation from Anthropic's Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception42, King Philanthropies, Global Innovation Fund, Nvidia, PostScriptum, Redalpine Venture Partners, Rockefeller Foundation, Singular, Sovereign AI, and True Ventures. Senior industry figures also invested, including André Hoffmann, Vice-Chairman of Roche. The funding will train a new generation of EDEN biological foundation models and advance a pipeline of AI-designed therapeutics toward clinical development, beginning with in vivo cell therapy. Basecamp combines frontier AI models trained on its proprietary Trillion Gene Atlas dataset with DNA-writing technology to reprogram patient cells to repair themselves, targeting cancer, autoimmune disease, and other conditions. The company reported strong preclinical results across multiple modalities and disease areas. Alongside the financing, Basecamp appointed Richard Pearce, formerly of Biogen, as Chief Business Officer, and Andy Conrad, General Partner at S32 and former CEO of Alphabet Inc. — Verily, joined its Board of Directors. The Trillion Gene Atlas was built with partners including Nvidia, Anthropic, Pacific Biosciences of California, and Ultima Genomics, drawing on biological data from access and benefit-sharing partnerships in more than 30 countries, including Malawi.

100 Basecamp Research raised $140M Series C
80 S32 led Series C Basecamp Research
50 Nvidia participated in financing Basecamp Research
50 Anthropic participated in financing Basecamp Research
40 André Hoffmann invested in financing Basecamp Research
40 Basecamp Research appointed Chief Business Officer Richard Pearce
30 Catalio Capital Management participated in financing Basecamp Research
30 European Tech Collective participated in financing Basecamp Research
30 Firebrand River Capital participated in financing Basecamp Research
30 Inception42 participated in financing Basecamp Research
30 King Philanthropies participated in financing Basecamp Research
30 Global Innovation Fund participated in financing Basecamp Research
30 PostScriptum participated in financing Basecamp Research
30 Redalpine Venture Partners participated in financing Basecamp Research
30 Rockefeller Foundation participated in financing Basecamp Research
+ 4 more actions View on Dashboard
priv
The central actor of the event, raising an oversubscribed $140M Series C to advance its EDEN-designed therapeutics pipeline and expand pharmaceutical partnerships. The funding strengthens its balance sheet and brings its in vivo cell therapy programs closer to clinical development.
Importance 100.0 Sentiment 60.0
priv
Led the $140M Series C and gained a board seat through General Partner Andy Conrad, deepening its position in AI-driven biotechnology.
Importance 70.0 Sentiment 40.0
priv
Its Anthology Fund participated in the round, and Anthropic collaborates with Basecamp on Claude Science and the Trillion Gene Atlas.
Importance 45.0 Sentiment 30.0
stock
Participated in the financing and is a partner in building the Trillion Gene Atlas, extending its AI ecosystem into life sciences.
Importance 45.0 Sentiment 30.0
per
Co-founder and CEO of Basecamp Research, he led the announcement and articulated the company's ambition to reprogram the body to repair itself.
Importance 40.0 Sentiment 30.0
per
The S32 General Partner and former Alphabet Inc. — Verily CEO joined Basecamp's Board of Directors, adding operational and healthcare-technology expertise.
Importance 35.0 Sentiment 25.0
stock
Its Vice-Chairman André Hoffmann invested personally and endorsed Basecamp's platform, signaling pharma interest in AI-designed therapeutics.
Importance 30.0 Sentiment 15.0
per
The Roche Vice-Chairman invested in the round and publicly backed Basecamp's full platform from biological data to designed therapies.
Importance 30.0 Sentiment 15.0
per
Formerly of Biogen, he was appointed Chief Business Officer to expand Basecamp's pharmaceutical partnerships.
Importance 30.0 Sentiment 20.0
priv
Participated in the Series C financing, gaining exposure to AI-designed therapeutics.
Importance 25.0 Sentiment 20.0
ngo
Participated in the Series C financing, marking continued NATO-linked investment in dual-use and frontier technology.
Importance 25.0 Sentiment 20.0
cnt
Hosts Basecamp's offices and labs in Cambridge, Massachusetts, where its therapeutic development and partnerships expand.
Importance 20.0 Sentiment 10.0
cnt
Home to Basecamp Research's London headquarters, benefiting from the company's growth and biotech investment.
Importance 20.0 Sentiment 10.0
priv
Participated in the Series C financing of Basecamp Research.
Importance 20.0 Sentiment 20.0
priv
Participated in the Series C financing of Basecamp Research.
Importance 20.0 Sentiment 20.0
+ 14 more entities View on Dashboard
Anthropic customer, investee ↔ Nvidia Anthropic is a key customer of Nvidia's AI GPUs and infrastructure, utilizing its hardware for scaling Claude models, an
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.